Aurinia Pharmaceuticals Inc. Diluted Shares Outstanding (Weighted Average)
Aurinia Pharmaceuticals Inc. (AUPH) reported Diluted Shares Outstanding (Weighted Average) of 133.53 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 133.53M shares, a 2.91% decline year-over-year.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 137.64M shares, a 3.88% decline year-over-year.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 137.92M shares, a 7.90% decline year-over-year.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 136.01M shares, a 6.62% decline year-over-year.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 138.70M shares, a 5.13% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 146.19M shares, a 2.07% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 143.24M shares, a 0.93% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 141.91M shares, a 9.70% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 133.53M shares 10-Q · filed 2026-08-06 | 135.52M shares 10-Q · filed 2026-08-06 | 136.36M shares derived: average of 3 quarters · filed 2026-08-06 | 136.28M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 137.64M shares 10-Q · filed 2026-05-07 | 137.78M shares derived: average of 2 quarters · filed 2026-05-07 | 137.19M shares derived: average of 3 quarters · filed 2026-05-07 | 137.27M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 137.92M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 136.97M shares derived: average of 2 quarters · filed 2026-02-26 | 137.15M shares derived: average of 3 quarters · filed 2026-08-06 | 138.70M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 136.01M shares 10-Q · filed 2025-11-04 | 136.77M shares derived: average of 2 quarters · filed 2026-08-06 | 138.96M shares 10-Q · filed 2025-11-04 | 141.62M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 137.53M shares 10-Q · filed 2026-08-06 | 140.19M shares 10-Q · filed 2026-08-06 | 143.49M shares derived: average of 3 quarters · filed 2026-08-06 | 144.03M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 143.20M shares 10-Q · filed 2026-05-07 | 146.47M shares derived: average of 2 quarters · filed 2026-05-07 | 146.20M shares derived: average of 3 quarters · filed 2026-05-07 | 145.68M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 149.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 147.70M shares derived: average of 2 quarters · filed 2026-02-26 | 146.50M shares derived: average of 3 quarters · filed 2026-02-26 | 146.19M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 145.65M shares 10-Q · filed 2025-11-04 | 144.88M shares derived: average of 2 quarters · filed 2025-11-04 | 145.01M shares 10-Q · filed 2025-11-04 | 144.37M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 144.11M shares 10-Q · filed 2025-07-31 | 143.51M shares 10-Q · filed 2025-07-31 | 143.94M shares derived: average of 3 quarters · filed 2026-02-26 | 143.66M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 144.01M shares 10-Q · filed 2025-05-12 | 143.85M shares derived: average of 2 quarters · filed 2026-02-26 | 143.52M shares derived: average of 3 quarters · filed 2026-02-26 | 143.33M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 143.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 143.27M shares derived: average of 2 quarters · filed 2026-02-26 | 143.10M shares derived: average of 3 quarters · filed 2026-02-26 | 143.24M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 142.85M shares 10-Q · filed 2024-11-07 | 142.81M shares derived: average of 2 quarters · filed 2024-11-07 | 143.09M shares 10-Q · filed 2024-11-07 | 142.61M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 142.78M shares 10-Q · filed 2024-08-01 | 142.90M shares 10-Q · filed 2024-08-01 | 142.53M shares derived: average of 3 quarters · filed 2025-02-27 | 142.36M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 142.64M shares 10-Q · filed 2024-05-02 | 142.40M shares derived: average of 2 quarters · filed 2025-02-27 | 142.22M shares derived: average of 3 quarters · filed 2025-02-27 | 142.10M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 142.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 142.01M shares derived: average of 2 quarters · filed 2025-02-27 | 141.92M shares derived: average of 3 quarters · filed 2025-02-27 | 141.91M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 141.86M shares 10-Q · filed 2023-11-02 | 141.79M shares derived: average of 2 quarters · filed 2023-11-02 | 141.83M shares 10-Q · filed 2023-11-02 | 139.62M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | 141.73M shares 10-Q · filed 2023-08-03 | 141.73M shares 10-Q · filed 2023-08-03 | 138.88M shares derived: average of 3 quarters · filed 2024-02-15 | 136.27M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | 141.68M shares 10-Q · filed 2023-05-04 | 137.45M shares derived: average of 2 quarters · filed 2024-02-15 | 134.45M shares derived: average of 3 quarters · filed 2024-02-15 | 132.89M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | 133.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 130.83M shares derived: average of 2 quarters · filed 2024-02-15 | 129.96M shares derived: average of 3 quarters · filed 2024-02-15 | 129.37M shares 10-K · filed 2024-02-15 |
| 2021-09-30 | 128.44M shares 10-Q · filed 2022-11-03 | 128.33M shares derived: average of 2 quarters · filed 2022-11-03 | 128.08M shares 10-Q · filed 2022-11-03 | 127.69M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 128.22M shares 10-Q · filed 2022-08-04 | 127.81M shares 10-Q · filed 2022-08-04 | 127.43M shares derived: average of 3 quarters · filed 2023-02-28 | 126.16M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 127.40M shares 10-Q · filed 2022-05-10 | 127.04M shares derived: average of 2 quarters · filed 2023-02-28 | 125.48M shares derived: average of 3 quarters · filed 2023-02-28 | 122.25M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 126.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 124.52M shares derived: average of 2 quarters · filed 2023-02-28 | 120.54M shares derived: average of 3 quarters · filed 2023-02-28 | 118.47M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 122.36M shares 10-Q · filed 2021-11-03 | 117.47M shares derived: average of 2 quarters · filed 2021-11-03 | 115.74M shares 10-Q · filed 2021-11-03 | |
| 2020-06-30 | 112.58M shares 10-Q · filed 2021-08-05 | 112.39M shares 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |